RxDoctor Payments Data

Stacy Smith, MD

Neuro-ophthalmology · Bellaire, TXNPI 1306138235

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $177,564 of the $224,723 with a category attached, or 79.0%. 52 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 31.1% of the total. Reporting peaked in 2020 at $78,515 and has fallen 58.1% since, to $32,889 in 2025.

$224,723in general payments, 2019–2025

Across 902 payments — averaging $249.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$70K
  • Lilly USA, LLC$65K
  • Pfizer$41K
  • AbbVie$24K
  • Biohaven Pharmaceutical Holding Company Ltd.$18K
  • AstraZeneca$937
  • plus $6K from 46 others

What the payments were for

  • Consulting fees$18,4838%
  • Speaking & faculty fees$177,56479%
  • Grants$440%
  • Travel & lodging$11,3355%
  • Food & beverage$17,2908%
  • Education$80%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuro-ophthalmology providers in Texasto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$157,803
Medicare patients
209
Services billed
14,869

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Nurtec OdtRimegepant Sulfate80$141,790
Aimovig AutoinjectorErenumab-Aooe66$59,870
UbrelvyUbrogepant42$59,794
QuliptaAtogepant52$56,674
Emgality PenGalcanezumab-Gnlm52$42,348
BotoxOnabotulinumtoxina11$14,348
Eletriptan HbrEletriptan Hydrobromide37$2,585
Sumatriptan Succinate79$2,010
Carbamazepine ErCarbamazepine11$1,902
RizatriptanRizatriptan Benzoate70$1,428
Topiramate88$1,185
Gabapentin75$997
Cyclobenzaprine Hcl60$749
Pyridostigmine Bromide15$731
Amitriptyline Hcl82$712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt$40,817$141,79080 claims
AbbVieUbrelvy, Qulipta, Botox$23,975$130,816105 claims
Upsher-smith Laboratories LLCTopiramate$96$1,18588 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$116$73115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few neuro-ophthalmology providers in Texason file to place this against a meaningful peer group, so we don't.

Other neuro-ophthalmology in Bellaire

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →